November 12, 2019   Investigator Q&A: Expanding Treatment Options for JIA In new research published in the New England Journal of Medicine, investigators led by William Tamborlane, M.D., a Yale University pediatric endocrinologist, reported the efficacy of the GLP1 agonist liraglutide for children with type 2 diabetes. In this Q&A, Dr. Tamborlane discusses the importance of expanding treatment options. Read more ADVERTISEMENT Dapagliflozin Benefits Heart Failure Patients, With or Without Diabetes The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine. Read more